Background {#Sec1}
==========

Chronic pancreatitis (CP) is a progressive inflammatory disease with irreversible destruction of the pancreatic parenchyma and ductal structures \[[@CR1]--[@CR5]\]. Autoimmune factor was regarded as one of the risk factors in the pathogenesis of CP. In 1995, Yoshida et al. \[[@CR6]\] proposed the concept of autoimmune pancreatitis (AIP) to define this particular type of CP. Now autoimmune is regarded as the major definite pathogenesis of AIP, but whether autoimmune factor plays a role in non-AIP CP or not was unknown. Presence of autoantibodies has been included in Japan \[[@CR7]\], Korean \[[@CR8]\] and Asian \[[@CR9]\] clinical diagnostic criteria for AIP, but clinical practice guidelines \[[@CR10], [@CR11]\] for CP had not clearly recommended whether autoantibody detection should be a conventional laboratory test or not. In the past few years, novel specific antibodies have emerged to help the diagnosis and differential diagnosis of AIP \[[@CR12]--[@CR14]\]. However, there have been no researches for specific antibodies of non-AIP CP. In the present study, we prospectively detected 22 common autoantibodies in 557 non-AIP CP patients to initially investigate the clinical significance of autoantibody detection.

Methods {#Sec2}
=======

Patient selection {#Sec3}
-----------------

Patients with CP admitted to the Department of Gastroenterology, Changhai Hospital for the first time from January 2010 to October 2016 were enrolled for the study mainly due to recurrent abdominal pain. For CP patients who did not experience pain, interventions were performed only when complications such as biliary stricture, pancreatic portal hypertension etc. had occurred, whereas diabetes mellitus and/or steatorrhea was not an indication for invasive treatment of CP. All patients underwent serum autoantibody detection at the time of hospital admission. Exclusion criteria were that: 1. Patients were formerly definitely diagnosed with AIP. 2. Combined with systemic lupus erythematosus, rheumatoid arthritis (RA), leukoderma, uarthritis or other autoimmune diseases before admission. 3. Autoimmune diseases were newly diagnosed within thirty days after autoantibody detection.

Data collection and detection of autoantibodies {#Sec4}
-----------------------------------------------

The following information was were prospectively collected: demographic data (age, sex, birthplace, et al), course of CP, medical history, history of other diseases, smoking and alcohol history, family history of pancreatic diseases and diabetes mellitus, laboratory and imaging findings, and treatment strategy.

Peripheral venous blood samples were obtained from all enrolled patients at admission to detect 22 common autoantibodies (EUROIMMUN Medical Laboratory Diagnostics Stock Company, Lübeck, German), whose sensitivity and specificity were provided in (see Additional file [1](#MOESM1){ref-type="media"}: Table S1). The distribution tested prior to using parametric tests of all autoantibodies was normal. Serum anti-double-stranded DNA (anti-ds DNA) antibody, anti-single-stranded DNA (anti-ss DNA) antibody, anti-SM antibody, anti-ribonucleoprotein (anti-RNP) antibody, anti SS-A antibody, anti SS-B antibody, anti-Jo-1 antibody, anti-Scl 70 antibody, anti-proliferating cell nuclear antigen antibody, anti-nucleosome antibodies, anti-histone antibody (AHA), anti-ribosomal antibody and anti-PM-Scl antibody were measured by EUROLINE according to the manufacturers' instructions. Serum samples were tested for anti-smooth muscle antibody (SMA), anti-mitochondrial antibody (AMA), anti-neutrophil cytoplasmic antibody and anti-neutrophil perinuclear antibody by indirect immunofluorescence. Serum anti-glomerular basement membrane antibody, anti-proteinase 3 IgG antibody, anti-myeloperoxidase antibody, anti-β2-glycoprotein I (β2-GPI) antibody and anticardiolipin (ACL) antibody were measured by enzyme-linked immunosorbent assay.

Search strategy {#Sec5}
---------------

In order to compare the frequency of autoantibodies between non-AIP CP patients and healthy controls, a literature search for autoantibodies with frequency \> 0.5% was performed through PubMed to identify eligible studies published. These literatures had to report the total positive rate of target autoantibody in historial healthy controls, and those literatures which only report the positive rate of some isoforms were excluded. These search strategy, which were defined prospectively, are provided in (see Additional file [1](#MOESM1){ref-type="media"}: Table S2). Then the frequency of target autoantibody in historial healthy controls was calculated by sum of cases in all enrolled studies.

Definitions {#Sec6}
-----------

The diagnosis of CP was established according to the Asia-Pacific consensus \[[@CR15]\]. The diagnosis of AIP was established according to the Asian diagnostic criteria \[[@CR9]\]. Alcoholic chronic pancreatitis (ACP) was diagnosed when alcohol intake exceeded 80 g/d for male and 60 g/d for female for at least two years in the absence of other causes, respectively \[[@CR16], [@CR17]\]. Heredity chronic pancreatitis was diagnosed when the CP patient had no less than two first-degree relatives with CP or recurrent acute pancreatitis, or no less than three second-degree relatives with CP or recurrent acute pancreatitis \[[@CR18]\]. We defined abnormal anatomy of pancreatic duct system (including pancreas divisum and anomalous pancreaticobiliary junction) as an etiology of CP in our study, although it still remains a controversy \[[@CR19]\]. A patient was defined as post-traumatic CP due to a definite history of abdominal trauma with imaging evidence of pancreatic injury and subsequent ductal dilation \[[@CR20]\]. CP patients were considered idiopathic chronic pancreatitis (ICP) when none of the above etiologies were found.

Statistical analysis {#Sec7}
--------------------

All analyses were performed using SPSS software (version 22.0, SPSS Inc.). Categorical variables were expressed as counts (percentages) and compared using the χ^2^ test, Fisher exact test or Mann-Whitney U test. Continuous variables were presented as mean ± standard deviation (SD). Multivariate logistic regression analysis was performed to identify the independent related factors of differentially expressed autoantibodies on the results of univariate analysis screening (factors with a significance level of *P* \< 0.15 were included in the multivariate analysis). Odds ratio (OR) and 95% confidence interval (CI) were calculated. Statistical analyses were conducted at a significance level of 0.05 for all analyses.

Results {#Sec8}
=======

General characteristics of Study subjects {#Sec9}
-----------------------------------------

After exclusion of 98 patients, which consists of 91 patients diagnosed with AIP, 3 patients diagnosed with uarthritis, 1 patient diagnosed with leukoderma, and 1 patient newly diagnosed with RA, a total of 575 non-AIP CP patients were finally enrolled in the study, including 393 males and 164 females. Their general characteristics were presented in Table [1](#Tab1){ref-type="table"}. The mean ± SD age at the onset and diagnosis of CP were 36.60 ± 16.59 and 41.53 ± 15.22 years old respectively. ICP was most common (70.4%) in this study.Table 1Clinical characteristics of 557 non-AIP CP patientsItemsMale (*n* = 393)\
n(%)Female (*n* = 164)\
n(%)Overall (*n* = 557)\
n(%)Body mass index, kg/m^2a^26.56 ± 105.9420.89 ± 3.5824.89 ± 89.01Age at the onset of CP, y^a^38.89 ± 15.8631.09 ± 17.0536.60 ± 16.59Age at the diagnosis of CP, y^a^43.60 ± 14.4036.57 ± 16.0041.53 ± 15.22Etiology ACP97(24.7)15(9.1)112(20.1) ICP266(67.7)126(76.8)392(70.4) Abnormal anatomy of pancreatic duct18(4.6)11(6.7)29(5.2) Hereditary CP11(2.8)11(6.7)22(3.9) Post-traumatic CP1(0.3)1(0.6)2(0.4)Pancreatic stones363(92.4)153(93.3)517(92.6)Adolescent40(10.2)32(19.5)72(12.9)DM102(26.0)33(20.1)135(24.2)Steatorrhea91(23.2)41(25.0)132(23.7)Common bile duct stricture40(10.2)7(14.9)47(8.4)PPC74(18.8)20(12.2)94(16.9)SAP13(3.3)4(2.4)17(3.0)Onset manifestations Abdominal pain320(81.4)116(70.7)436(78.3) Pancreatic insufficiency53(13.5)35(21.3)88(15.8) Others20(5.1)13(7.9)33(5.9)Type of abdominal pain None31(7.9)26(15.9)57(10.2) Repeat attacks of acute pancreatitis120(30.5)45(27.4)165(29.6) Repeat pain138(35.1)57(34.8)195(35.0) Repeat acute attacks and pain71(18.1)25(15.2)96(17.2) Chronic pain33(8.4)11(6.7)44(7.9)Drinking history (g/d) 0223(56.7)130(79.3)353(63.4) \< 2013(3.3)5(3.0)18(3.2) 20\~8053(13.5)10(6.1)63(11.3) \> 80104(26.5)19(11.6)123(22.1)^b^Smoking history, pack-year 0212(53.9)130(79.3)342(61.4) \< 60161(41.0)32(19.5)193(34.6) ≥ 6020(5.1)2(1.2)22(3.9)DM in first−/second−/third-degree relatives57(14.5)28(17.1)85(15.3)Pancreatic diseases in first−/second−/third-degree relatives12(3.1)7(4.3)19(3.4)Elevated IgG^c^16(4.1)3(1.8)19(3.4)Elevated IgG4^c^19(4.8)2(1.2)21(3.8)*CP* Chronic pancreatitis, *ACP* Alcoholic chronic pancreatitis, *AIP* Autoimmune pancreatitis, *ICP* Idiopathic chronic pancreatitis, *DM* Diabetes mellitus, *PPC* Pancreatic pseudocyst, *SAP* Severe acute pancreatitis^a^Mean ± SD^b^123 patients with drinking history \> 80 g/d included 112 cases with ACP, 7 cases with hereditary CP, 3 cases with anatomical abnormality and one case with post-traumatic CP^c^Serum IgG and IgG4 were measured by immunoturbidimetry assay (Immage800 specific protein analyzer, Beckman, USA; BN2 specific protein analyzer, Siemens, Germany), and their upper limits were 15.6 g/l and 2.0 g/l respectively

Comparison of frequency of autoantibodies between non-AIP CP patients and historial healthy controls {#Sec10}
----------------------------------------------------------------------------------------------------

In this study, we selected autoantibodies with frequency \> 0.5% (β2-GPI, SMA, ACL, AMA, anti SS-B, anti-ds DNA, anti-ss DNA, AHA, anti-RNP, anti-proteinase 3 IgG antibody) in non-AIP CP patients as search objects to compare and analyze, which were listed in Table [2](#Tab2){ref-type="table"}. We identified 86 relevant citations through PubMed to be enrolled in this study (Additional file [1](#MOESM1){ref-type="media"}: Table S2). Then the frequency of these autoantibodies in non-AIP CP patients and historial healthy controls were calculated and compared respectively. χ^2^ or Fisher exact test results showed that the frequencies of serum β2-GPI and anti SS-B antibody in patients were significantly higher than that in historial healthy controls, and the frequencies of serum SMA and ACL antibody in patients were significantly lower than that in historial healthy controls (all *P* \< 0.05).Table 2Comparison of positive rate of nine autoantibodies between non-AIP CP patients and historial healthy controlsAutoantibodynon-AIP CP patientsHistorial Healthy controls*P*PositiveNegativeFrequency (%)PositiveNegativeFrequency (%)Anti-β2-glycoprotein I antibody515069.163718391.97\< 0.001Anti-smooth muscle antibody175403.05243027.360.003Anticardiolipin antibody165412.879314316.100.003Anti-mitochondrial antibody95481.621413401.030.224Anti SS-B antibody95481.62416590.24\< 0.001Anti-double-stranded DNA antibody85491.44020200.190Anti-single-stranded DNA antibody65511.08145682.410.088Anti-histone antibody55520.90147111.930.129Anti-ribonucleoprotein antibody35540.541310781.190.201Anti-proteinase 3 IgG antibody35540.54023700.558Anti-PM-Scl antibody25550.36--------Anti-neutrophil cytoplasmic antibody25550.36--------Anti-ribosomal antibody25550.36--------Anti SS-A antibody15560.18--------Anti-Jo-1 antibody15560.18--------Anti-SM antibody15560.18--------Anti-myeloperoxidase antibody15560.18--------anti-neutrophil perinuclear antibody15560.18--------Anti-proliferating cell nuclear antigen antibody15560.18--------Anti-Scl 70 antibody05560--------Anti-nucleosome antibodies05560--------Anti-glomerular basement membrane antibody05560--------*CP* Chronic pancreatitis, *AIP* Autoimmune pancreatitis

Related factors for positive β2-GPI antibody in non-AIP CP patients {#Sec11}
-------------------------------------------------------------------

As there were significant differences in frequency of serum β2-GPI, anti SS-B, SMA and ACL antibody between non-AIP CP patients and historial healthy controls, the relationship between these 4 autoantibodies and clinical characteristics were analyzed in non-AIP CP patients. The potential related factors were listed in Table [3](#Tab3){ref-type="table"} and were analyzed in the univariate analysis. As illustrated in Table [4](#Tab4){ref-type="table"}, four variables showed a *P* value less than 0.15 in the univariate logistic regression analysis screening, and they were selected as candidates for multivariate logistic regression analysis. The result showed that diabetes mellitus (DM) in first−/second−/third-degree relatives (OR = 0.266, *P* = 0.033) was the protective factor of positive β2-GPI antibody while DM (OR = 2.768, *P* = 0.001) and common bile duct stricture (OR = 2.952, *P* = 0.007) were the risk factors. There were no related factors for other three differentially expressed autoantibodies (all *P* \> 0.05), which were showed in (see Additional file [1](#MOESM1){ref-type="media"}: Table S3--S6).Table 3Related factors for positive β2-GPI antibody in non-AIP CP patients \[n(%)\]PredictorsPositiven(*n* = 51)Negetive(*n* = 506)*P*Female sex15(29.4)149(29.4)0.996BMI, kg/m^2^21.49 ± 3.06^a^25.23 ± 93.390.775Age at the onset of CP, y^a^40.31 ± 18.54^a^36.22 ± 16.360.093Age at the diagnosis of CP, y^a^46.09 ± 15.33^a^41.07 ± 15.150.135Etiology0.410 ACP6(11.8)106(20.9) ICP41(80.4)351(69.4) Abnormal anatomy of pancreatic duct1(2.0)28(5.5) Hereditary CP3(5.9)19(3.8) Post-traumatic CP0(0)2(0.4)Pancreatic stones46(90.2)470(92.9)0.675Adolescent5(9.8)67(13.2)0.486DM22(43.1)113(22.3)0.001Steatorrhea14(27.5)118(23.3)0.508Common bile duct stricture11(19.6)37(7.3)0.006PPC8(15.7)86(17.0)0.812SAP2(3.9)15(3.0)1.000Onset manifestations0.110 Abdominal pain35(68.6)401(79.2) Pancreatic insufficiency10(19.6)78(15.4) Others6(11.8)27(5.3)Type of pain0.576 None7(13.7)50(9.9) Repeat attacks of acute pancreatitis14(27.5)151(29.8) Repeat pain21(41.2)174(34.4) Repeat acute attacks and pain7(13.7)89(17.6) Chronic pain2(3.9)42(8.3)Drinking history (g/d)0.078 038(74.5)315(62.3)  \< 201(2.0)17(3.4) 20\~805(9.8)58(11.5)  \> 807(13.7)116(22.9)Smoking history, pack-year0.020 039(76.5)303(59.9) \< 6011(21.6)182(36.0) ≥ 601(2.0)21(4.2)DM in first−/second−/third-degree relatives3(5.9)82(16.2)0.051Pancreatic diseases in first−/second−/third-degree relatives0(0)19(3.8)0.316Elevated IgG^b^3(5.9)16(3.2)0.538Elevated IgG4^b^5(9.8)16(3.2)0.047*CP* Chronic pancreatitis, *ACP* Alcoholic chronic pancreatitis, *AIP* Autoimmune pancreatitis, *ICP* Idiopathic chronic pancreatitis, *DM* Diabetes mellitus, *PPC* Pancreatic pseudocyst, *SAP* Severe acute pancreatitis^a^Mean ± SD^b^Serum IgG and IgG4 were measured by immunoturbidimetry assay (Immage800 specific protein analyzer, Beckman, USA; BN2 specific protein analyzer, Siemens, Germany), and their upper limits were 15.6 g/l, 2.0 g/l respectivelyTable 4Related factors for positive β2-GPI antibody in non-AIP CP patientsPredictorsUnivariate AnalysisMultivariate AnalysisOR(95% CI)*P*OR(95% CI)*P*Female sex1.042(0.509--2.130)0.911BMI, kg/m^2^0.998(0.987--1.009)0.751Age at the onset of CP, y^a^0.992(0.954--1.031)0.684Age at the diagnosis of CP, y^a^1.028(0.986--1.071)0.195Etiology0.812 ACPControl ICP0.991(0.059--16.668)0.995 Abnormal anatomy of pancreatic duct0.377(0.013--11.052)0.571 Hereditary CP1.770(0.164--19.055)0.638 Post-traumatic CP0(0)0.999Pancreatic stones0.680(0.220--2.103)0.503Adolescent1.167(0.318--4.284)0.816DM2.315(1.174--4.566)0.0152.768(1.510--5.072)0.001Steatorrhea1.462(0.705--3.033)0.307Common bile duct stricture2.785(1.159--6.693)0.0222.952(1.343--6.489)0.007PPC0.938(0.397--2.215)0.883SAP0.906(0.160--5.139)0.911Onset manifestations0.240 Abdominal painControl Pancreatic insufficiency1.081(0.414--2.821)0.874 Others2.949(0.780--11.145)0.111Type of pain0.879 NoneControl Repeat attacks of acute pancreatitis1.131(0.292--4.377)0.858 Repeat pain1.121(0.331--3.797)0.854 Repeat acute attacks and pain1.132(0.245--5.243)0.874 Chronic pain0.470(0.070--3.155)0.437Drinking history (g/d)0.828 0Control  \< 200.488(0.056--4.282)0.517 20\~800.649(0.209--2.138)0.497  \> 800.634(0.043--9.452)0.741Smoking history, pack-year0.445 0Control  \< 600.565(0.230--1.386)0.213  ≥ 600.533(0.058--4.928)0.579DM in first−/second−/third-degree relatives0.272(0.076--0.076)0.0450.266(0.079--0.897)0.033Pancreatic diseases in first−/second−/third-degree relatives0(0)0.999Elevated IgG^b^1.639(0.409--6.564)0.485Elevated IgG4^b^2.797(0.814--9.614)0.103*CP* Chronic pancreatitis, *ACP* Alcoholic chronic pancreatitis, *AIP* Autoimmune pancreatitis; *ICP* Idiopathic chronic pancreatitis, *DM* Diabetes mellitus, *PPC* Pancreatic pseudocyst, *SAP* Severe acute pancreatitis^a^Mean ± SD^b^Serum IgG and IgG4 were measured by immunoturbidimetry assay (Immage800 specific protein analyzer, Beckman, USA; BN2 specific protein analyzer, Siemens, Germany), and their upper limits were 15.6 g/l, 2.0 g/l respectively

Discussion {#Sec12}
==========

To our knowledge, the current study is the first study to compare the frequency of autoantibodies between non-AIP CP patients and historial healthy controls. This study totally detected 22 autoantibodies in 575 non-AIP CP patients after exclusion of patients combined with or newly diagnosed of other autoimmune diseases. Four autoantibodies (β2-GPI, anti SS-B, SMA and ACL antibody) were expressed differentially between non-AIP CP patients and historial healthy controls. DM in first−/second−/third-degree relatives was the protective factor of positive β2-GPI antibody while DM and common bile duct stricture were the risk factors. And there were no related factors for other three differentially expressed autoantibodies.

β2-GPI antibody, a major antigenic target for antiphospholipid antibodies, was the most frequent autoantibody in non-AIP CP patients. β2-GPI antibody could bine to negatively charged phospholipids and inhibit the coagulation cascade and platelet function \[[@CR21]\]. Previous study had demonstrated that β2-GPI could interact with oxidized low density lipoprotein to form β2-GPI-ox-LDL complexes, and serum levels of β2-GPI-ox-LDL complexes were significantly elevated in autoimmune disorders, which may reliably help to predict the development of autoimmune-mediated atherosclerosis \[[@CR22]\]. This present study showed that frequency of β2-GPI antibody in non-AIP CP patients was significantly higher than that in historial healthy controls (9.16% vs. 1.97%, *P* \< 0.001). Multivariate logistic regression analysis result showed that DM and common bile duct stricture were risk factors of positive β2-GPI antibody while DM in first/second/third degree relatives was a protective factor. But there is no previous study to confirm the relationship between β2-GPI antibody and family history of DM, CBD stricture. Only a few studies have showed that β2-GPI antibody may participate in the occurrence and development of DM \[[@CR23]\]. Cojocaru et al. \[[@CR24]\] indicated that the positive rate of anti-IgG β2-GPI in type 2 diabetes mellitus patients with diabetic retinopathy (DR) was significantly higher than that in patients without DR (85% vs. 21%, RR 4.640). However, Tarkun et al. \[[@CR25]\] found that there was no significant association between β2-GPI antibody and vascular complications in type 2 diabetes mellitus patients, so β2-GPI antibody may not have a major role in the pathogenesis of diabetic complications in type 2 diabetes mellitus patients. In brief, it's unclear whether β2-GPI antibody was related to the occurrence and development of clinical events of CP until now.

At present, CP is regarded as a disease with multiple etiological factors including alcohol, autoimmunity, biliary tract diseases, etc. And alcohol and autoimmunity factors may coexist. In the past, patients suspected of CP admitted to our center for the first time would be received history taking, physical examination, imaging examination and laboratory examination (including serum autoantibody detection) for diagnosis, etiology identification, treatment guidance and prognosis evaluation. The present study determined four differentially expressed autoantibodies between non-AIP CP patients and historial healthy controls, among them β2-GPI antibody were expressed most frequently. As β2-GPI antibody was independently associated with DM and common bile duct stricture, it may be a potential serum marker to predict the occurrence of these clinical events. Although previous studies found several serum markers for early diagnosis \[[@CR26]\] and differential diagnosis \[[@CR27]\] of CP, they were not widely used in clinic practice. Until now, the diagnosis of CP is mainly based on the clinical manifestation and imaging findings. Although this current study identified four differentially expressed autoantibodies between non-AIP CP patients and historial healthy controls, they had limited value in diagnosing non-AIP CP, and could not help the differentiation of non-AIP CP from other pancreatic diseases including pancreatic cancer, intraductal papillary mucinous neoplasm of the pancreas, cystic pancreatic lesions and so on because of low specificity \[[@CR28]\]. And there is no research to confirm that these four autoantibodies are protective against development of CP up to now. Therefore, we don't recommend that autoantibodies test should be a conventional examination for diagnosis and differential diagnosis of CP unless suspected of AIP, whose several diagnostic criteria \[[@CR7]--[@CR9]\] had include presence of autoantibodies. Another recent study in our center showed that the positive rates of antinuclear antibody, anti-SSA antibody, and anti-SSB antibody of patients with AIP were 17.1, 11.4 and 8.6% respectively, and then we considered that autoantibody could be a subsidiary indicator for the diagnosis of AIP \[[@CR29]\]. Treatment options of CP mainly include pancreatic enzyme replacement therapy, insulin infusion injection, endoscopic therapy and surgery, which were mostly determined by clinical symptom, blood sugar level, imaging findings and patients' subjective will. Although the presence of autoantibodies were related with DM and common bile duct stricture in this present study, they could not be served as predictors for the clinical events, and had little significance in guiding clinical treatments and evaluating curative effect until now.

There are several limitations of the present study. Firstly, the observational study design (cohort study) is inherent to selection bias. And we chose control group through literature search in PubMed due to difficulty for large-scale collecting the serum of healthy people to detect all antibodies in clinical, but the historial healthy controls may increase the inaccuracy of target autoantibodies' frequencies as there may be differences among different races, countries, regions and nations. Secondly, this study lack of estimate on causality between autoantibody and CP occurrence as the samples were tested once disease had occurred. Thirdly, this current study belongs to cross-sectional study, so it is not clearly whether autoantibody test could predict the occurrence of clinical events and treatment prognosis of CP.

Conclusions {#Sec13}
===========

Four autoantibodies were expressed differentially between non-AIP CP patients and historial healthy controls. Due to limited significance for diagnosis and treatment of CP, autoantibodies detection is not recommended conventionally unless suspected of AIP.

Additional file
===============

 {#Sec14}

Additional file 1:**Table S1.** Sensitivity and specificity of test method of 22 autoantibodies. Peripheral venous blood samples were obtained from all enrolled patients at admission to detect 22 common autoantibodies (EUROIMMUN Medical Laboratory Diagnostics Stock Company, Lübeck, German), whose sensitivity and specificity were provided in Additional file [1](#MOESM1){ref-type="media"}: Table S1. **Table S2.** Search strategy and result in PubMed (up until May 4th, 2017) In order to compare the frequency of autoantibodies between non-AIP CP patients and healthy controls, a literature search for autoantibodies with frequency \> 0.5% was performed through PubMed to identify eligible studies published. These search strategy and result are provided in Additional file [1](#MOESM1){ref-type="media"}: Table S2. **Table S3.** Univariate analysis for smooth muscle antibody, anticardiolipin antibody and anti SS-B antibody in non-AIP CP patients \[n(%)\]. Univariate analysis result showed that there were no significant differences in all clinical data between patients with positive and negative other three differentially expressed autoantibodies (smooth muscle antibody, anticardiolipin antibody and anti SS-B antibody) (all *P* \> 0.05). **Table S4.** Related factors for positive smooth muscle antibody in non-AIP CP patients. Univariate logistic regression analysis result showed that there were no related factors for positive smooth muscle antibody in non-AIP CP patients (*P* \> 0.05). **Table S5.** Related factors for positive anticardiolipin antibody in non-AIP CP patients. Univariate logistic regression analysis result showed that there were no related factors for positive anticardiolipin antibody in non-AIP CP patients (*P* \> 0.05). **Table S6.** Related factors for positive anti SS-B antibody in non-AIP CP patients. Univariate logistic regression analysis result showed that there were no related factors for positive anti SS-B antibody in non-AIP CP patients (*P* \> 0.05). (DOCX 165 kb)
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